2012-10-10 21:25:44 - Fast Market Research recommends "Leg Ulcers - Pipeline Review, H2 2012" from Global Markets Direct, now available

Global Markets Direct's, 'Leg Ulcers - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Leg Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Leg Ulcers. Leg Ulcers - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/468461_leg_ulcers_pipeline_review_h2_2012.as ..


Note*: Certain sections in the report may be removed or altered based on the availability and

relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Leg Ulcers.
* A review of the Leg Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Leg Ulcers pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Leg Ulcers.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Leg Ulcers pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Leg Ulcers Overview
Therapeutics Development
An Overview of Pipeline Products for Leg Ulcers
Leg Ulcers Therapeutics under Development by Companies
Leg Ulcers Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Leg Ulcers Therapeutics - Products under Development by Companies
Leg Ulcers Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Leg Ulcers Therapeutics Development
Sanofi-Aventis
CytoTools AG
Healthpoint, Ltd.
Glycotex, Inc.
Phage Biotechnology Corporation
CoDa Therapeutics, Inc.
Adocia
Leg Ulcers - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Mebo - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GLYC-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DermaPro - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FGF-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biochaperone PDGF-BB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HP802-247 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HO/03/03 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nexagon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LyphoDerm - Drug Profile
Product Description
Mechanism of Action
R&D Progress
WPP-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sodium nitrite - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vasculotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LL-37 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Leg Ulcers Therapeutics - Drug Profile Updates
Leg Ulcers Therapeutics - Discontinued Products
Leg Ulcers Therapeutics - Dormant Products
Leg Ulcers - Product Development Milestones
Featured News & Press Releases
Aug 02, 2012: Healthpoint Biotherapeutics Announces Publication Of Phase IIb Study Results Of Investigational Cell-Based Therapy In Lancet
Jul 25, 2012: Healthpoint Biotherapeutics Announces Phase II Trial Results Of HP802-247 For Venous Leg Ulcers
Jan 09, 2012: NovaBay Pharmaceuticals Announces Strategic Marketing Agreement For NeutroPhase In China
Aug 04, 2011: Healthpoint Biotherapeutics Announces Positive Results From Phase IIb Trial Of HP802-247 In Venous Leg Ulcers
Mar 26, 2009: RegeneRx Reports Phase II Venous Stasis Trial Results
Feb 26, 2009: RegeneRx Updates On Phase II Venous Stasis Trial
Dec 20, 2004: RegeneRx Files With FDA For Second Phase II Clinical Trial

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468461&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.